Nimesulida Neuride (Nimesulide)

Nimesulide is indicated for several pain‑related and inflammatory conditions, acting through COX‑2 inhibition to reduce prostaglandin‑mediated symptoms.

• Mild to moderate pain: provides analgesic relief for acute or chronic pain such as headache or musculoskeletal discomfort.
• Osteoarthritis: reduces joint inflammation and improves mobility in patients with degenerative joint disease.
• Dysmenorrhea: alleviates menstrual cramps by decreasing uterine prostaglandin production.

• Nimesulide selectively inhibits the cyclooxygenase‑2 (COX‑2) enzyme, which catalyzes the conversion of arachidonic acid to prostaglandins involved in inflammation, pain and fever. By blocking COX‑2, the drug lowers prostaglandin synthesis at sites of tissue injury while sparing COX‑1 activity, thereby providing anti‑inflammatory and analgesic effects with a reduced risk of gastrointestinal irritation compared with non‑selective NSAIDs.

Nimesulide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Skin rash or mild itching.
• Elevated liver enzymes detected in routine tests.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury or hepatitis.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Renal impairment: acute kidney injury or worsening chronic kidney disease.
• Cardiovascular events: increased risk of thrombotic events or hypertension.
• Anaphylaxis: life‑threatening allergic reaction.

When prescribing Nimesulide, clinicians should consider several precautionary measures to minimize risk.

• Assess liver function: avoid use in patients with active hepatic disease or elevated transaminases.
• Evaluate renal status: use cautiously in those with impaired kidney function.
• Monitor gastrointestinal risk: patients with a history of ulcers or bleeding should be closely observed.
• Review cardiovascular history: avoid in individuals with uncontrolled hypertension or recent thrombotic events.
• Check concomitant medications: avoid combining with other COX‑2 inhibitors or hepatotoxic drugs.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Nimesulide can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.
• Hepatotoxic agents (e.g., isoniazid, methotrexate): heightened liver injury risk.
• Lithium: reduced renal clearance leading to toxicity.
• ACE inhibitors or diuretics: may diminish antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• SSRIs or SNRIs: modest increase in bleeding tendency.
• Corticosteroids: enhanced risk of gastrointestinal ulceration.
• Cyclosporine: possible increase in nephrotoxicity.
• Oral hypoglycemics: may affect blood glucose control.
• Antiretrovirals (e.g., protease inhibitors): potential alteration of drug metabolism.